cr1447
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2016 (NCT02067741)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Estrogen receptor betaAGONIST
ESR2 agonist
Main metabolite is ESR2 agonist (:http://www.curadis.eu/index.php?page=cr-1447)
- Androgen ReceptorAGONIST
AR agonist
Main metabolite is ESR2 agonist (:http://www.curadis.eu/index.php?page=cr-1447)
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545092 ↗
Also known as
- cr1447
- cr 1447
- cr-1447
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02067741 | Phase 2 | May 1, 2016 | Cantonal Hospital of St. Gallen, Swiss Group for Clinical Cancer Research, University of Bern |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cantonal Hospital of St. Gallen | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Swiss Group for Clinical Cancer Research | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Bern | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1